Design Therapeutics

Design Therapeutics

DSGN· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +52.0% in FY2025

Pratik Shah, Ph.D. is the CEO of Design Therapeutics and was paid $3.5M in FY2025 (Dec), up 349%.

Pay$100 in the stock at the end of FY21 → $170
CEO pay is from each Design Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Pratik Shah, Ph.D.FY2025
  2. 2Sean Jeffries, Ph.D.FY2025
  3. 3Chris M. Storgard, M.D.Not disclosed

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Design Therapeutics paid its 2 named executives $5.4M in total in FY2025 (Dec). CEO Pratik Shah, Ph.D. was paid $3.5M of that.

Name
Pratik Shah, Ph.D.President, Chief Executive Officer and ChairpersonNot disclosed
Sean Jeffries, Ph.D.Chief Operating OfficerNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Design Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board5

See all
  • Simeon George, M.D.Lead independent director · 4 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive
  • John SchmidDirector · 4 yr on the boardIndependentAudit, Compensation—Paid as an executive
  • Arsani William, M.D.Director · 3 yr on the boardIndependentAudit, Compensation—Paid as an executive
  • Deepa PrasadDirector · 3 yr on the boardIndependentAudit—Paid as an executive
  • Heather Berger, Ph.D.Director · 3 yr on the boardIndependentAudit, Research and Development—Paid as an executive

The board of the latest proxy (FY2024).

Activity

Filings6

See all
Proxy statementDEF 14AApr 23, 2026FY2025
Annual report10-KMar 9, 2026FY2025
Proxy statementDEF 14AApr 24, 2025FY2024
Annual report10-KMar 10, 2025FY2024
Proxy statementDEF 14AApr 25, 2024FY2023
Annual report10-KMar 19, 2024FY2023